Insulet Names Eric Benjamin as New COO

Insulet has appointed Eric Benjamin as its new Chief Operating Officer, effective immediately. Benjamin has been with the company since 2015 and has led key initiatives including the launches of Omnipod DASH and Omnipod 5.

In a strategic move, Insulet Corporation has appointed Eric Benjamin as its new Chief Operating Officer, effective immediately. Benjamin, a 10-year veteran of the company, has played a pivotal role in shaping Insulet's product roadmap and customer-centric ethos. He has led key initiatives, including the launches of the Omnipod DASH and Omnipod 5 systems, digitizing customer engagement, and expanding into the type 2 diabetes market [2].

The appointment of Benjamin as COO aligns with Insulet's ongoing strategic leadership changes aimed at driving global expansion and innovation in diabetes technology. This move signals a bold new era of innovation and commercialization for the company. Benjamin's extensive experience within Insulet, coupled with his track record of launching successful products and expanding into new markets, positions him well to oversee Strategy & Business Development, R&D, and the newly formed Growth organization [2].

In addition to the appointment of Benjamin, Insulet has appointed Manoj Raghunandanan as Chief Growth Officer. Raghunandanan brings over two decades of global consumer health experience, having led a $6 billion OTC portfolio at Kenvue (formerly Johnson & Johnson Consumer Health). His expertise in commercial excellence and market expansion will be crucial as Insulet targets international growth in markets like Australia, New Zealand, and Japan [2].

These leadership changes are part of Insulet's broader strategy to capture a significant share of the $20 billion global diabetes technology market. The company's financial strength, demonstrated by a 31% year-over-year increase in Q2 2025 revenue to $649 million, highlights its ability to reinvest in innovation while maintaining profitability [2].

Insulet's financial discipline, raising full-year revenue guidance to 24-27% and gross margins to 71%, underscores its commitment to balancing reinvestment with profitability. The company's robust financial foundation and pipeline of next-generation products position it as a compelling long-term investment opportunity [2].

However, investors should be aware of potential risks, including regulatory hurdles and competition from established players like Medtronic and Dexcom. Insulet's pharmacy-based distribution model and affordability (as low as $1/day) create a durable competitive moat, offering a strong defense against these challenges [2].

In conclusion, the appointment of Eric Benjamin as COO and Manoj Raghunandanan as CGO reflects Insulet's commitment to innovation and global expansion. With a strong financial foundation and a clear strategy for international growth, Insulet offers a promising long-term investment opportunity.

References:
[1] https://www.tradingview.com/news/tradingview:fe581c18319f9:0-insulet-corp-executive-sells-shares/
[2] https://www.ainvest.com/news/insulet-strategic-leadership-reinvention-growth-potential-2508/
[3] https://www.ainvest.com/news/stock-analysis-insulet-outlook-balancing-strong-fundamentals-uncertain-technicals-2508/